Daiichi Sankyo mRNA vaccine DS-5670 Phase I/II clinical trial in Japan begins immunization

At present, the new crown pneumonia epidemic abroad is still spreading rapidly.

Recently, Daiichi Sankyo announced that the Phase I/II clinical trial of the novel coronavirus pneumonia (COVID-19) mRNA vaccine (DS-5670) in Japan has begun to vaccinate subjects.

mRNA is a nucleic acid molecule that carries genetic information.

At present, the mRNA vaccine Comiranty (BNT162b2) from Pfizer/BioNTech and the mRNA vaccine mRNA-1273 from Moderna have obtained emergency use authorization/temporary authorization/conditional approval in many countries around the world.

Just recently, Moderna announced that its new-generation vaccine mRNA-1283 has been immunized in the first phase of clinical trials for the first batch of subjects.

DS-5670 is developed using Daiichi Sankyo's proprietary new nucleic acid delivery technology.

In this phase 1/2 clinical trial currently being carried out in Japan, a total of 152 healthy adults (including the elderly) were enrolled for the purpose of evaluating the safety and immunogenicity of the vaccine, thereby estimating the recommended dose of DS-5670.

At present, the field of COVID-19 vaccine research and development is developing at an unprecedented scale and speed.

At the same time, as of March 16, 2021, more than 200 vaccine candidates are under development, of which 82 vaccines are in clinical development and 182 vaccines are in preclinical development.

Of the 82 vaccines in the clinical development stage, most (71 vaccines) mainly adopt the following 5 technical routes: protein subunits (PS, n=27, 33%), viral vectors (non-replicating, VVnr, n= 12.

Among the 82 vaccines, 12 (15%) were single-dose immunizations, 50 were 2-dose immunizations (61%), 1 was 3-dose immunizations (1%), and 19 (23%) were not confirmed or no data.

Note: The original text has been deleted

Original source: Daiichi Sankyo, World Health Organization, Bio Valley